Role of SGLT-2 inhibitors in chronic heart failure treatment

• Elena K. Serezhina
• Andrey G. Obrezan

Abstract

Currently, chronic heart failure is one of the most common pathologies, the incidence of which is steadily increasing. Due to the great social, economic and medical significance of this problem, complex drug therapy is needed to improve the clinical picture, prognosis and reduce the mortality of patients. It is necessary to supplement existing therapeutic strategies with new pharmacological drugs that have high efficiency, a wide therapeutic window and minimal side effects to achieve these goals. This review discusses four studies dedicated to reveal the effect of SGLT-2 inhibitors on the cardiovascular system in patients with cardiovascular pathology in order to enable the inclusion this group of drugs in the treatment heart failure.

Keywords:heart failure, SGLT-2 inhibitors, EMPA-REG, CANVAS, DAPA-HF, DECLARE-TIMI58

References

1. Shah K.S., Xu H., Matsouaka R.A., et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017; 70 (20): 2476–86.

2. Koufou E.E., Arfaras-Melainis A., Rawal S., et al. Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence. J Clin Med. 2021; 10 (2): 203. DOI: https://www.doi.org/10.3390/jcm10020203.

3. Lytvyn Y., Bjornstad P., Udell J.A., et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017; 136 (17): 1643–58. DOI: https://www.doi.org/10.1161/CIRCULATIONAHA.117.030012.

4. Inzucchi S.E., Khunti K., Fitchett D.H., et al. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab. 2020; 105 (9): 3025–35. DOI: https://www.doi.org/10.1210/clinem/dgaa321.

5. Inzucchi S.E., Zinman B., Fitchett D., et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018; 41: 356–63.

6. Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. 377: 644–57.

7. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–57.

8. Kato E.T., Silverman M.G., Mosenzon O., et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019; 139: 2528–36.

9. Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovasc Diabetol. 2019; 18 (1): 129. DOI: https://www.doi.org/10.1186/s12933-019-0938-6.

10. Bertero E., Prates Roma L., Ameri P., Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018; 114: 12–8.

11. Serenelli M., et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European heart journal. 2020; 41 (36): 3402–18. DOI: https://www.doi.org/10.1093/eurheartj/ehaa496.

12. Verma S. Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits. Am J Cardiol. 2019; 124: S36–S44.

13. Mizuno Y., Harada E., Nakagawa H., et al. The diabetic heart utilizes ketone bodies as an energy source. Metabolism. 2017; 77: 65–72.

14. Voros G., Ector J., Garweg C., et al. Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling. Circ Heart Fail. 2018; 11: e004953.

15. Mudaliar S., Alloju S., Henry R.R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care. 2016; 39: 1115–22.

16. Wang J., Hu X., Jiang H. HDAC inhibition: a novel therapeutic approach for attenuating heart failure by suppressing cardiac remodeling // Int J Cardiol. 2016; 214: 41–2.

17. Kimura I., Inoue D., Maeda T., et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci USA. 2011; 108: 8030–5.

18. Sano M., Chen S., Imazeki H., et al. Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig. 2018; 9: 638–41.

19. Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019; 139: 1985–7.

20. Lambers Heerspink H.J., de Zeeuw D., Wie L., Leslie B., List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15: 853–62.

21. Mazer C.D., Hare G.M.T., Connelly P.W., et al. Effect of empagliflozin on erythropoietin levels, iron stores and red blood cell morphology in patients with type 2 diabetes and coronary artery disease. Circulation. 2020; 141: 704–7.

22. McMurray J.J.V., Solomon S.D., Inzucchi S.E., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995–2008.

23. Sano M., Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019; 139: 1985–7.

24. Takaori K., Nakamura J., Yamamoto S., et al. Severity and frequency of proximal tubule injury determines renal prognosis. J Am Soc Nephrol. 2016; 27: 2393–406.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)